DISCLAIMER
DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.
GlaxoSmithKline launches mini Nicorette lozenges
GlaxoSmithKline said Tuesday it is selling a fast-dissolving lozenge version of its Nicorette anti-smoking lozenges.
The British drugmaker said the new mini lozenge dissolves up to three times faster than similar products. It is designed to help relieve nicotine cravings and withdrawal symptoms, and comes in a small pocket-size vial. The company is launching the lozenges with a campaign that includes a Facebook contest.
GlaxoSmithKline reported about $529 million in nicotine replacement therapy revenue in 2009, including sales of Nicorette gum, Nicoderm CQ patches and Commit lozenges.
Free Book "Make Real Money on the Internet" from world’s #1 internet wealth advocate Absolutely free!
Claim Your Free Copy!
Posts
No comments:
Post a Comment